Adelaide Research & Scholarship: Search

Search

Results 1-9 of 9 (Search time: 0.002 seconds).

previous
1
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2014	The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17	Sommeijer, D.; Karapetis, C.; Zalcberg, J.; Tu, D.; Jonker, D.; Simes, J.; Tebbutt, N.; Yip, D.; Price, T.; O'Callaghan, C.
	2015	Does the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review and meta-analysis of the literature	Chan, D.; Pavlakis, N.; Shapiro, J.; Price, T.; Karapetis, C.; Tebbutt, N.; Segelov, E.; Rosell, R.
	2015	Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer	Price, T.; Bruhn, M.; Lee, C.; Hardingham, J.; Townsend, A.; Mann, K.; Simes, J.; Weickhardt, A.; Wrin, J.; Wilson, K.; Gebski, V.; Van Hazel, G.; Robinson, B.; Cunningham, D.; Tebbutt, N.
	2012	Biologic therapies in the metastatic colorectal cancer treatment continuum - applying current evidence to clinical practice	Peeters, M.; Price, T.
	2008	K-ras mutations and benefit from cetuximab in advanced colorectal cancer	Karapetis, C.; Khambata-Ford, S.; Jonker, D.; O'Callaghan, C.; Tu, D.; Tebbutt, N.; Simes, R.; Chalchal, H.; Shapiro, J.; Robitaille, S.; Price, T.; Shepherd, L.; Au, H.; Langer, C.; Moore, M.; Zalcberg, J.
	2010	Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer	Peeters, M.; Price, T.; Cervantes, A.; Sobrero, A.; Ducreux, M.; Hotko, Y.; Andre, T.; Chan, E.; Lordick, F.; Punt, C.; Strickland, A.; Wilson, G.; Ciuleanu, T.; Roman, L.; Van Cutsem, E.; Tzekova, V.; Collins, S.; Oliner, K.; Rong, A.; Gansert, J.
	2012	Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: Preclinical evaluation and results of the Phase II DUX Study in chemotherapy-refractory, advanced colorectal cancer	Weickhardt, A.; Price, T.; Chong, G.; Gebski, V.; Pavlakis, N.; Johns, T.; Azad, A.; Skrinos, E.; Fluck, K.; Dobrovic, A.; Salemi, R.; Scott, A.; Mariadason, J.; Tebbutt, N.
	2012	Cetuximab in metastatic colorectal cancer	Broadbridge, V.; Karapetis, C.; Price, T.
	2015	Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI zlone as second-line treatment for metastatic colorectal cancer	Peeters, M.; Oliner, K.; Price, T.; Cervantes, A.; Sobrero, A.; Ducreux, M.; Hotko, Y.; André, T.; Chan, E.; Lordick, F.; Punt, C.; Strickland, A.; Wilson, G.; Ciuleanu, T.; Roman, L.; Van Cutsem, E.; He, P.; Yu, H.; Koukakis, R.; Terwey, J.; et al.